Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-005-0145-xPMID 16341532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiogenesis spectrum in the stroma of B‐cell non‐Hodgkin's lymphomas. An immunohistochemical and ultrastructural study

  2009cited by this paper
• The liposomal formulation of doxorubicin.

  2005cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

  2004cited by this paper
• Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia

  2004cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses

  2004cited by this paper
• Angiogenesis in hematologic malignancies.

  2003cited by this paper
• Effects of cell damage and glycosaminoglycan degradation on available extravascular space of different dextrans in a rat fibrosarcoma

  2003cited by this paper
• Angiogenic and Lymphangiogenic Molecules in Hematological Malignancies

  2002cited by this paper
• The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.

  2001cited by this paper
• Angiogenesis in Lymphoproliferative Disorders

  2001cited by this paper
• Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.

  2001cited by this paper
• Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.

  2001cited by this paper
• Available Space and Extracellular Transport of Macromolecules: Effects of Pore Size and Connectedness

  2001cited by this paper
• Angiogenesis in hematologic malignancies

  2001cited by this paper
• Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B‐cell non‐Hodgkin's lymphomas

  2000cited by this paper
• Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.

  1999cited by this paper
• Antiangiogenesis is produced by nontoxic doses of vinblastine.

  1999cited by this paper
• Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery.

  1999influential reference
• Noninvasive visualization of tumors in rodent dorsal skin window chambers

  1999cited by this paper
• Vincristine revisited.

  1999cited by this paper
• Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.

  1998cited by this paper
• Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.

  1998cited by this paper
• Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer

  1998cited by this paper
• Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.

  1997cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

  1995cited by this paper
• Liposomes revisited

  1995cited by this paper
• Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristine encapsulated in sterically stabilised liposomes.

  1995cited by this paper
• Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.

  1995cited by this paper
• Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.

  1995cited by this paper
• Pharmacokinetics and anti‐tumor activity of vincristine encapsulated in sterically stabilized liposomes

  1995cited by this paper
• Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.

  1995cited by this paper
• Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

  1994cited by this paper
• Vinca alkaloids: anti-vascular effects in a murine tumour.

  1993cited by this paper
• Measurement of material extravasation in microvascular networks using fluorescence video-microscopy.

  1993cited by this paper
• Liposomes : a practical approach

  1990cited by this paper
• Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.

  1990cited by this paper
• Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

  1984cited by this paper
• Treatment of advanced non‐Hodgkin's lymphoma with vincristine infusion

  1984cited by this paper
• Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.

  1982cited by this paper
• THE COLORIMETRIC DETERMINATION OF PHOSPHORUS

  1925cited by this paper

• 3D-printed lightweight dorsal skin fold chambers from PEEK reduce chamber-related animal distress

  2022cites this paper
• Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles

  2018cites this paper
• Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine

  2018cites this paper
• Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

  2016influential citation
• Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies

  2014cites this paper
• Evaluation of doxorubicin-loaded pH-sensitive polymeric micelle release from tumor blood vessels and anticancer efficacy using a dorsal skin-fold window chamber model

  2014cites this paper
• Ability of co-administered peptide liposome nanoparticles to exploit tumour acidity for drug delivery

  2014cites this paper
• Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

  2012cites this paper
• Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

  2012cites this paper
• Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors

  2012cites this paper
• Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function

  2011cites this paper
• Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.

  2010cites this paper
• Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles

  2010cites this paper
• Molecular Cancer apeutics apeutic Discovery 7 , a Novel Antimitotic Indole , Displays a Potent In vitro and Ther ivo Antitumor Activity with Less Neurotoxicity

  2010cites this paper
• I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity

  2010cites this paper
• DNA loaded carrier preferential extravasation from tumor blood vessel.

  2009cites this paper
• Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

  2008cites this paper
• Development and Evaluation of Brain Tumor Targeted Liposome Delivery System for Paclitaxel

  2007cites this paper
• Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy.

  2006cites this paper